Results 251 to 260 of about 102,788 (290)

IGHV1 usage is associated with lymphadenopathy and aggressive disease in the TCL1 mouse model for chronic lymphocytic leukemia

open access: yes
Drothler S   +9 more
europepmc   +1 more source

Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia [PDF]

open access: possibleClinical Lymphoma, 2004
Chronic lymphocytic leukemia (CLL) is the most frequent form of leukemia in the Western hemisphere.1 In this disease, a clonal proliferation of neoplastic B lymphocytes accumulates in bone marrow, blood, lymph nodes, liver, and spleen. According to the World Health Organization (WHO) classification, B-cell CLL is a mature (peripheral) B-cell neoplasm ...
Michael L. Grossbard, Ilan Shapira
openaire   +2 more sources

Targeting B-cell anergy in chronic lymphocytic leukemia [PDF]

open access: possibleBlood, 2013
Key Points A sizable fraction of CLL patients is characterized by the expansion of clonal B cells with anergic features. The constitutive biochemical signature of B-cell anergy can be efficiently targeted in CLL for therapeutic purposes.
Apollonio B   +10 more
openaire   +3 more sources

The Origin of B-Cell Chronic Lymphocytic Leukemia

Seminars in Oncology, 2006
An immunobiologic approach has led to substantial changes in our current view of chronic lymphocytic leukemia (CLL). Several questions remain unsolved and the definition of the cell origin of CLL is still prominent. The presence of somatic mutations of IGHV genes indicates that, at least in a portion of cases, CLL cells had encountered an antigen ...
GHIA , PAOLO PROSPERO   +1 more
openaire   +3 more sources

Cytokines in B-Cell Chronic Lymphocytic Leukemia

Leukemia & Lymphoma, 1991
The pleomorphic action of different cytokines in regulating the growth and proliferation of normal B- and T-lymphocyte populations is becoming progressively more apparent. Thus, the possibility that some cytokines, either alone or in variable combination, may play a role in different lymphoproliferative disorders has been increasingly suggested and ...
FOA, Roberto   +7 more
openaire   +4 more sources

Histopathology of B-cell chronic lymphocytic leukemia

Hematology/Oncology Clinics of North America, 2004
Histologic and immunohistologic findings of B-cell chronic lymphocytic leukemia/small lymphocytic leukemia are revised in the light of the more recent knowledge on the pathobiology of the disease. The guidelines for the optimal handling of the bioptic samples are provided. The relevance of the examination of trephines and surgical specimens is outlined
PILERI, STEFANO   +6 more
openaire   +3 more sources

Rituximab in B-Cell chronic lymphocytic leukemia

Seminars in Oncology, 2003
The monoclonal anti-CD20 antibody rituximab exerts its antitumor activity through a variety of mechanisms, including acting against the cellular defects in apoptosis that give rise to B-chronic lymphocytic leukemia (B-CLL). Phase II clinical studies demonstrated that rituximab, given weekly as a single agent, exhibits significantly less activity in B ...
Thomas S. Lin   +2 more
openaire   +3 more sources

Chronic Myelomonocytic Leukemia Coexisting with B-cell Chronic Lymphocytic Leukemia

Leukemia & Lymphoma, 2003
Coexistence of B-cell chronic lymphocytic leukemia (B-CLL) and chronic myelomonocytic leukemia (CMML) is an unusal event, and to our knowledge, only four such cases have been reported in the literature. We report a 68-year-old white woman in whom these two diseases were diagnosed concomitantly.
Ewa Wawrzyniak   +6 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy